Evaluation of TP53 codon 72 polymorphism in esophageal cancer susceptibility in Eastern Anatolia Region of Turkey


Kaya Z., Almalı N., Karan B. M. , Görgişen G.

The Eastern Journal of Medicine, vol.26, no.3, pp.388-395, 2021 (Peer-Reviewed Journal)

  • Publication Type: Article / Article
  • Volume: 26 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.5505/ejm.2021.65707
  • Journal Name: The Eastern Journal of Medicine
  • Journal Indexes: Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.388-395

Abstract


 The tumor suppressor TP53 gene plays a key role in the regulation of cell cycle. Polymorphisms in this gene have been associated with many cancers including esophageal cancer (EC). Many studies in other populations have demonstrated that codon 72 polymorphism of TP53 gene contribute to the prediction of EC risk, especially in Asians. The aim of this study was to explore the effect of codon 72 polymorphism on the EC risk in eastern Turkey. 

The codon 72 polymorphism was genotyped by real time polymerase chain reaction (qPCR) with TaqMan SNP genotyping assay in 79 patients and 80 healthy control subjects. 

No statistically significant difference was observed in distribution of genotype and allele frequencies. Heterozygous Arg/Pro (CG) was the most frequent genotype in both patients and controls. Homozygous Arg/Arg (GG) genotype frequency was higher in patients than controls, but not statistically significant (p>0.05). However, tumor location in the lower part of the esophagus was significantly higher in non-C carriers (GG, Arg/Arg) compared to C-carriers (CG/CC) (p=0.01). G-carriers were also more likely to have poorer survival compared to patients with CC genotype (p=0.04). 

Our results suggest that the Codon 72 polymorphism was not associated with the EC in eastern Turkey. However, GG genotype (Arg/Arg) may have a role in tumor development at the lower location of the esophagus. Additionally, G carriers may exist the poorer survival compared to the non-G carriers (CC). Therefore, it is thought that individuals with CC genotype (Pro/Pro) may have better survival.